Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory del Zoppo, Peter Sandercock, Richard L Lindley, Geoff Cohen, Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory del Zoppo, Peter Sandercock, Richard L Lindley, Geoff Cohen
Abstract
Background: Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.
Methods: We searched for randomised trials of intravenous rt-PA versus control given within 6 h of onset of acute ischaemic stroke up to March 30, 2012. We estimated summary odds ratios (ORs) and 95% CI in the primary analysis for prespecified outcomes within 7 days and at the final follow-up of all patients treated up to 6 h after stroke.
Findings: In up to 12 trials (7012 patients), rt-PA given within 6 h of stroke significantly increased the odds of being alive and independent (modified Rankin Scale, mRS 0-2) at final follow-up (1611/3483 [46·3%] vs 1434/3404 [42·1%], OR 1·17, 95% CI 1·06-1·29; p=0·001), absolute increase of 42 (19-66) per 1000 people treated, and favourable outcome (mRS 0-1) absolute increase of 55 (95% CI 33-77) per 1000. The benefit of rt-PA was greatest in patients treated within 3 h (mRS 0-2, 365/896 [40·7%] vs 280/883 [31·7%], 1·53, 1·26-1·86, p<0·0001), absolute benefit of 90 (46-135) per 1000 people treated, and mRS 0-1 (283/896 [31·6%] vs 202/883 [22·9%], 1·61, 1·30-1·90; p<0·0001), absolute benefit 87 (46-128) per 1000 treated. Numbers of deaths within 7 days were increased (250/2807 [8·9%] vs 174/2728 [6·4%], 1·44, 1·18-1·76; p=0·0003), but by final follow-up the excess was no longer significant (679/3548 [19·1%] vs 640/3464 [18·5%], 1·06, 0·94-1·20; p=0·33). Symptomatic intracranial haemorrhage (272/3548 [7·7%] vs 63/3463 [1·8%], 3·72, 2·98-4·64; p<0·0001) accounted for most of the early excess deaths. Patients older than 80 years achieved similar benefit to those aged 80 years or younger, particularly when treated early.
Interpretation: The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with favourable outcome and alive and independent at final follow-up. The data strengthen previous evidence to treat patients as early as possible after acute ischaemic stroke, although some patients might benefit up to 6 h after stroke.
Funding: UK Medical Research Council, Stroke Association, University of Edinburgh, National Health Service Health Technology Assessment Programme, Swedish Heart-Lung Fund, AFA Insurances Stockholm (Arbetsmarknadens Partners Forsakringsbolag), Karolinska Institute, Marianne and Marcus Wallenberg Foundation, Research Council of Norway, Oslo University Hospital.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures
References
- The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581–1587.
- Hacke W, Kaste M, Fieschi C. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA. 1995;274:1017–1025.
- Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet. 1998;352:1245–1251.
- Wardlaw JM, Sandercock PAG, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke. Where do we go from here? A cumulative meta-analysis. Stroke. 2003;34:1437–1442.
- Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003 CD000213.
- Hacke W, Donnan G, Fieschi C. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774.
- Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329.
- Lees KR, Bluhmki E, von Kummer R. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet. 2010;375:1695–1703.
- Wardlaw JM, Murray VE, Berge E, del Zoppo GJ. Thrombolysis in acute ischaemic stroke. Cochrane Database Syst Rev. 2009;4 CD000213.
- Wardlaw JM, Sandercock PA, Murray V. Should more patients with acute ischaemic stroke receive thrombolytic treatment? BMJ. 2009;339:b4584.
- Wardlaw JM, Warlow CP. Thrombolysis in acute ischaemic stroke: does it work? Stroke. 1992;23:1826–1839.
- Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy— I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81–106.
- Mori E, Yoneda Y, Tabuchi M. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42:976–982.
- Yamaguchi T, Hayakawa T, Kiuchi H, for the Japanese Thrombolysis Study Group Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993;3:269–272.
- Haley EC, Jr, Brott TG, Sheppard GL. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke. 1993;24:1000–1004.
- Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0– to 6–hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31:811–816.
- Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019–2026.
- Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke. 2002;33:493–495.
- Wang SY, Wang XL, Zeng H. Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003;15:542–545.
- Davis SM, Donnan G, Parsons MW. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.
- The IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012 published online May 23.
- Bruins Slot K, Berge E, Dorman P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336:376–379.
- Mishra NK, Ahmed N, Andersen G. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
- Bhatnagar P, Sinha D, Parker RA, Guyler P, O'Brien A. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry. 2011;82:712–717.
- Lorenzano S, Toni D, for the TESPI trial Investigators TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset. Int J Stroke. 2012;7:250–257.
- Ma H, Parsons MW, Christensen S. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) Int J Stroke. 2012;7:74–80.
Source: PubMed